Epidemiology and Clinical Impact of Clonal Hematopoiesis in People With HIV.

BACKGROUND: Clonal hematopoiesis (CH), defined by the expansion of hematopoietic cells with somatic mutations in leukemogenic genes (CH of indeterminate potential [CHIP]) or with mosaic chromosomal alterations (mCAs), is associated with aging and adverse health outcomes in the general population. Clonal hematopoiesis of indeterminate potential prevalence is higher in people with human immunodeficiency virus (PWH) than in controls. However, the full spectrum, prevalence, and clinical consequences of CH in PWH remain incompletely understood. METHODS: We assessed CHIP and mCAs in a large sample of PWH (N∼2500) from the Swiss HIV Cohort Study. Using high-depth targeted sequencing of CHIP genes and genome-wide genotyping to call mCAs, we quantified the prevalence and clone size of both CH types and investigated an association of CH with clinical variables. RESULTS: Clonal hematopoiesis of indeterminate potential (25% of individuals) and mCAs (16% of individuals) were common, positively correlated with age, often co-occurring (odds ratio = 1.7, P = .02 for autosomal mCAs), and associated with various clinical outcomes, including all-cause mortality (hazard ratio [HR] = 1.3, P = .02 for CHIP) and hematologic malignancies (HR = 9.4, P = .01 for the effect of CHIP on the risk of myeloid cancer; HR > 20, P < .001 for the effect of co-occurring CHIP and mCAs on the risk of lymphoid cancer). We also observed associations of CH with several proxies of inflammatory status (CD4:CD8 ratio, HIV load, late initiation of antiretroviral therapy, and toxicity of antiretroviral drugs). CONCLUSIONS: The study provides a comprehensive assessment of the CH landscape in PWH, highlighting potential causes and consequences in this population and suggesting an interaction between CH and chronic immune activation.

Authors

Publication Details

Journal
Open Access CRIS of the University of Bern
Published
2026-11-16
DOI
https://doi.org/10.48620/99842
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Epidemiology and Clinical Impact of Clonal Hematopoiesis in People With HIV.

PHILIP E. TARR, Laura Naëmi Walti, Matthias L. Cavassini, Alexander G. Bick et al.
1 links
Open Access CRIS of the University of Bern
Acute Myeloid Leukemia Research
article

Epidemiology and Clinical Impact of Clonal Hematopoiesis in People With HIV.

PHILIP E. TARR, Laura Naëmi Walti, Matthias L. Cavassini, Alexander G. Bick, Gioele Capoferri, Huldrych F. Günthard, Christian Wandall Thorball, Jacques Fellay, Mariam Ait Oumelloul, Valeriia Timonina, Alexandra Calmy, Patrick Schmid, Konstantin Popadin
article en

Abstract

BACKGROUND: Clonal hematopoiesis (CH), defined by the expansion of hematopoietic cells with somatic mutations in leukemogenic genes (CH of indeterminate potential [CHIP]) or with mosaic chromosomal alterations (mCAs), is associated with aging and adverse health outcomes in the general population. Clonal hematopoiesis of indeterminate potential prevalence is higher in people with human immunodeficiency virus (PWH) than in controls. However, the full spectrum, prevalence, and clinical consequences of CH in PWH remain incompletely understood. METHODS: We assessed CHIP and mCAs in a large sample of PWH (N∼2500) from the Swiss HIV Cohort Study. Using high-depth targeted sequencing of CHIP genes and genome-wide genotyping to call mCAs, we quantified the prevalence and clone size of both CH types and investigated an association of CH with clinical variables. RESULTS: Clonal hematopoiesis of indeterminate potential (25% of individuals) and mCAs (16% of individuals) were common, positively correlated with age, often co-occurring (odds ratio = 1.7, P = .02 for autosomal mCAs), and associated with various clinical outcomes, including all-cause mortality (hazard ratio [HR] = 1.3, P = .02 for CHIP) and hematologic malignancies (HR = 9.4, P = .01 for the effect of CHIP on the risk of myeloid cancer; HR > 20, P < .001 for the effect of co-occurring CHIP and mCAs on the risk of lymphoid cancer). We also observed associations of CH with several proxies of inflammatory status (CD4:CD8 ratio, HIV load, late initiation of antiretroviral therapy, and toxicity of antiretroviral drugs). CONCLUSIONS: The study provides a comprehensive assessment of the CH landscape in PWH, highlighting potential causes and consequences in this population and suggesting an interaction between CH and chronic immune activation.

Open Access CRIS of the University of Bern
Good health and well-being
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon